• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Repeated Changes to the Gravitational Field Negatively Affect the Serum Concentration of Select Growth Factors and Cytokines
This study was carried out in accordance with the recommendations of the ethical committee of the Ruhr-Universität Bochum with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the ethical committee of the Ruhr-Universität Bochum (Register-Number 5158–14). Author Contributions US, FS, LG, and AK performed the experiments. US and TR analyzed the data, created the figures, and drafted the manuscript. TW, FS, and NB designed the study. All authors revised the manuscript and approved its fina...
Source: Frontiers in Physiology - April 16, 2019 Category: Physiology Source Type: research

YiQiFuMai Powder Injection Attenuates Coronary Artery Ligation-Induced Heart Failure Through Improving Mitochondrial Function via Regulating ROS Generation and CaMKII Signaling Pathways
This study was carried out in accordance with the recommendations of “Guide for the Care and Use of Laboratory Animals, National Institutes of Health.” The protocol was approved by the “China Pharmaceutical University.” Surgical Preparation The mice were anesthetized with chloral hydrate (4% chloral hydrate, ip). The HF model was induced by CAL as previously reported (Gao et al., 2010). Successful ligation of the coronary artery was confirmed by the occurrence of ST-segment elevation in electrocardiogram. Sham operated mice were performed the same process except left CAL. After ligation, the h...
Source: Frontiers in Pharmacology - April 9, 2019 Category: Drugs & Pharmacology Source Type: research

Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time
Conclusion: CVD is a common complication in MM patients: within 5 years of a MM diagnosis, over 25% develop CVD requiring hospitalization. Contrary to our hypothesis, we did not find increased CVD admissions in the most recent era. Decreased admissions due to CHF and CAD in the most recent era of diagnosis may indicate a greater awareness of this issue, routine thromboprophylaxis with anti-platelet agents in patients being treated with immunomodulatory agents, or changes in secular trends in the diagnosis and treatment of CVD. CVD is an ongoing source of morbidity for MM patients requiring further study and the vigilance o...
Source: Blood - November 21, 2018 Category: Hematology Authors: Rosenberg, A. S., Li, Q., Brunson, A. M., Tuscano, J., Wun, T., Keegan, T. H. M. Tags: 904. Outcomes Research-Malignant Conditions: Poster II Source Type: research

Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.
CONCLUSIONS: This systematic review and meta-analysis found moderate quality evidence that BMSC treatment improves LVEF. Unlike in trials where BMSC were administered following acute myocardial infarction (AMI), we found some evidence for a potential beneficial clinical effect in terms of mortality and performance status in the long term (after at least one year) in people who suffer from chronic IHD and heart failure, although the quality of evidence was low. PMID: 24777540 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - May 3, 2014 Category: Journals (General) Authors: Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E Tags: Cochrane Database Syst Rev Source Type: research

Predictive Risk Factors of In-Hospital Mortality Following Acute Stroke in the United States: Data from the Nationwide Inpatient Database, 2006-2010 (P02.015)
CONCLUSIONS: The rate of in-hospital mortality is relatively high following acute stroke (8.42%). We identified multiple risk factors of in-hospital mortality in acute stroke patients. The strongest risk factor is the type stroke (hemorrhagic). The present finding suggests that patients at increased risk of mortality can be identified and additional treatment for prevention might be warranted.Disclosure: Dr. Naderi has nothing to disclose. Dr. Abcede has nothing to disclose. Dr. Al-Khoury has nothing to disclose. Dr. Mozaffar has received personal compensation for activities with California Stem Cell Inc., NuFactor, Cresce...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Naderi, N., Abcede, H., Al-Khoury, L., Mozaffar, T., Jain, V. Tags: P02 Cerebrovascular Disease II Source Type: research